The goal of the proposed project is to develop an HIV vaccine platform for delivery of HIV ENV immunogen that presents antigen as native conformation and induces bnabs.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93022C00013
- Awardee
-
Genecure LLC UEI LFPEB7MMJCG3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · SBIRPHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $300,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Norcross, GA, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $300,000 |
About this award
Genecure LLC has been awarded a $300,000 firm fixed price Small Business Innovation Research contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is associated with an NIH/CDC SBIR solicitation seeking proposals to develop medical technologies, diagnostics, vaccines, cell therapies and other innovative solutions to advance public health goals.
Under this contract, Genecure will develop an HIV vaccine platform to deliver HIV envelope immunogens in their native conformation and induce broadly neutralizing antibodies, in alignment with NIAID's mission to conduct and support research to understand, treat and prevent infectious diseases including HIV/AIDS. Place of performance is in Norcross, Georgia and work will be conducted over a period of 15 months from July 2022 through August 2023. The award is set aside for total small business participation.
Quick answers
Who was awarded contract 75N93022C00013?
75N93022C00013 was awarded to Genecure LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2022.
How much is contract 75N93022C00013 worth?
The government has obligated $300,000 on 75N93022C00013.
Was contract 75N93022C00013 competed?
The extent of competition for 75N93022C00013 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award